Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
about
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.
P2860
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@ast
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@en
type
label
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@ast
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@en
prefLabel
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@ast
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@en
P2093
P2860
P1433
P1476
Gemcitabine, dexamethasone, an ...... phoma-not otherwise specified.
@en
P2093
Changgong Zhang
Jianliang Yang
Sheng Yang
Shengyu Zhou
Weihu Wang
Xiaohui He
P2860
P304
P356
10.1007/S00277-016-2877-6
P577
2016-11-17T00:00:00Z